Insider · CIK 0001813310
Cavu Advisors, LLC
ownerdirector
Files at CGTX (COGNITION THERAPEUTICS INC), ACTU (ACTUATE THERAPEUTICS, INC.), INAB (IN8BIO, INC.), LTRN (Lantern Pharma Inc.). First filing Aug 14, 2024, latest Aug 20, 2024.
In brief
Cavu Advisors, LLC files SEC Form 4 as 10% owner and director at ACTU (ACTUATE THERAPEUTICS, INC.), and also at CGTX (COGNITION THERAPEUTICS INC), INAB (IN8BIO, INC.), LTRN (Lantern Pharma Inc.). Since Aug 14, 2024, Cavu Advisors, LLC has reported 1 open-market buy worth $4.0M and 2 open-market sells worth $425k, the latest filed on Aug 20, 2024.
A track record needs three past buys with six months of prices behind them; Cavu Advisors, LLC has 0, so none is measured yet.
The newest scored trade: sold $200k of ACTU on Aug 14, 2024, filed Aug 20, 2024, scored 42 (moderate).
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 2
$4.0M bought, $425k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ACTU: ACTUATE THERAPEUTICS, INC.
ACTUOct 12, 2026 · close 0.64
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 42Moderate | ACTUATE THERAPEUTICS, INC. | $200k 24,999 shares | -8% | +6% from low0% from high | |
| 75Notable | ACTUATE THERAPEUTICS, INC. | $4.0M 500,000 shares | +57% | +6% from low0% from high | |
| 42Moderate | ACTUATE THERAPEUTICS, INC. | $225k 24,999 shares | -8% | +6% from low0% from high |
Transactions
The newest 50 of 59 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: Directly held by Bios Fund II, LP | -5,314 | $8.00 | $43k | 300,143 | Aug 20, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: Directly held by Bios Fund II QP, LP | -17,361 | $8.00 | $139k | 980,433 | Aug 20, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: Directly held by Bios Fund II NT, LP | -2,324 | $8.00 | $19k | 131,248 | Aug 20, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Common Stockindirect: Directly held by Bios Clinical Opportunity Fund, LP | +884,427 | - | - | 884,427 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | POpen-market purchase Common Stockindirect: Directly held by Bios Clinical Opportunity Fund, LP | +375,000 | $8.00 | $3.0M | 1,259,427 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | POpen-market purchase Common Stockindirect: Directly held by Bios 2024 Co-Invest, LP | +125,000 | $8.00 | $1.0M | 125,000 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Common Stockindirect: Directly held by Bios Fund I, LP | +525,797 | - | - | 525,797 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Common Stockindirect: Directly held by Bios Fund I QP, LP | +307,538 | - | - | 307,538 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Common Stockindirect: Directly held by Bios Fund II, LP | +141,457 | - | - | 141,457 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Common Stockindirect: Directly held by Bios Fund II QP, LP | +462,073 | - | - | 462,073 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Common Stockindirect: Directly held by Bios Fund II NT, LP | +61,857 | - | - | 61,857 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Common Stockindirect: Directly held by Bios Actuate Co-Invest I, LP | +153,702 | - | - | 153,702 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Common Stockindirect: Directly held by Bios Fund II, LP | +54,032 | - | - | 195,489 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Common Stockindirect: Directly held by Bios Fund II QP, LP | +176,499 | - | - | 638,572 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Common Stockindirect: Directly held by Bios Fund II NT, LP | +23,628 | - | - | 85,485 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Common Stockindirect: Directly held by Bios Actuate Co-Invest I, LP | +147,047 | - | - | 300,749 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Common Stockindirect: Directly held by Bios Fund II, LP | +101,900 | - | - | 297,389 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Common Stockindirect: Directly held by Bios Fund II QP, LP | +332,867 | - | - | 971,439 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Common Stockindirect: Directly held by Bios Fund II NT, LP | +44,559 | - | - | 130,044 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Common Stockindirect: Directly held by Bios Fund III, LP | +309,589 | - | - | 309,589 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Common Stockindirect: Directly held by Bios Fund III QP, LP | +2,022,029 | - | - | 2,022,029 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Common Stockindirect: Directly held by Bios Fund III NT, LP | +326,547 | - | - | 326,547 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Common Stockindirect: Directly held by Bios Actuate Co-Invest II, LP | +2,094,650 | - | - | 2,094,650 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Common Stockindirect: Directly held by Bios Fund III, LP | +74,202 | - | - | 383,791 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Common Stockindirect: Directly held by Bios Fund III QP, LP | +484,638 | - | - | 2,506,667 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Common Stockindirect: Directly held by Bios Fund III NT, LP | +78,267 | - | - | 404,814 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Common Stockindirect: Directly held by Bios Actuate Co-Invest III, LP | +573,394 | - | - | 573,394 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | XIn-the-money exercise Common Stockindirect: Directly held by Bios Fund II, LP | +8,068 | $5.27 | $43k | 305,457 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: Directly held by Bios Fund II, LP | -5,314 | $9.00 | $48k | 300,143 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | XIn-the-money exercise Common Stockindirect: Directly held by Bios Fund II QP, LP | +26,355 | $5.27 | $139k | 997,794 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: Directly held by Bios Fund II QP, LP | -17,361 | $9.00 | $156k | 980,433 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | XIn-the-money exercise Common Stockindirect: Directly held by Bios Fund II NT, LP | +3,528 | $5.27 | $19k | 133,572 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | SOpen-market sale Common Stockindirect: Directly held by Bios Fund II NT, LP | -2,324 | $9.00 | $21k | 131,248 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Convertible Notederivativeindirect: Directly held by Bios Clinical Opportunity Fund, LP | -884,427 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Series A Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund I, LP | -525,797 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Series A Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund I QP, LP | -307,538 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Series B-1 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund II, LP | -141,457 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Series B-1 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund II QP, LP | -462,073 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Series B-1 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund II NT, LP | -61,857 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Series B-1 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Actuate Co-Invest I, LP | -153,702 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Series B-2 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund II, LP | -54,032 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Series B-2 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund II QP, LP | -176,499 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Series B-2 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund II NT, LP | -23,628 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Series B-2 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Actuate Co-Invest I, LP | -147,047 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Series B-3 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund II, LP | -101,900 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Series B-3 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund II QP, LP | -332,867 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Series B-3 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund II NT, LP | -44,559 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Series B-4 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund III, LP | -309,589 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Series B-4 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund III QP, LP | -2,022,029 | - | - | 0 | Aug 14, 2024 |
| Aug 14, 2024 | ACTU ACTUATE THERAPEUTICS, INC. | CConversion Series B-4 Redeemable Convertible Preferred Stockderivativeindirect: Directly held by Bios Fund III NT, LP | -326,547 | - | - | 0 | Aug 14, 2024 |
50 of 59 rows shown.
Questions about Cavu Advisors, LLC
Answered from the filings on this page, as of the latest one.
Is Cavu Advisors, LLC buying or selling?
Not in the last 12 months. Cavu Advisors, LLC's latest open-market trade on SEC Form 4 was sold $200k of ACTU on Aug 14, 2024.
How did Cavu Advisors, LLC's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Cavu Advisors, LLC has 0.
Where does Cavu Advisors, LLC file Form 4?
Cavu Advisors, LLC has filed Form 4 at ACTU (ACTUATE THERAPEUTICS, INC.); CGTX (COGNITION THERAPEUTICS INC); INAB (IN8BIO, INC.); LTRN (Lantern Pharma Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.